Why the study?
Dexmedetomidine is commonly used as a sedative during critical illness, but its potential accelerative effect on LPS-mediated cardiac fibroblast differentiation and underlying mechanism were unexplored.
Population
Wild-type and α2A-AR knockout mice and isolated mouse cardiac fibroblasts
Comparison
Dexmedetomidine vs control in LPS-stimulated conditions
Design
Preclinical animal and cell-culture study
Authors
Loading...
Hypothesis-generating for DEX effects on cardiac fibrosis in sepsis models; leaves open human relevance and clinical sedation choices.
Dexmedetomidine accelerates LPS-induced cardiac fibroblast differentiation and fibrosis via the α2A-AR/PKC-p38-Smad2/3 pathway in mice.
Liao et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: